Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Hairy Cell 1

Interventions

Cytarabine 10venetoclax 8Rituximab 7Daunorubicin 7nilotinib 6Azacitidine 6blinatumomab 5Bendamustine Hydrochloride 5bosutinib 4Imatinib Mesylate 4obinutuzumab 3asciminib 3acalabrutinib 3Mitoxantrone 3Methotrexate 3Etoposide 3Dexamethasone 3Decitabine 3Dasatinib 3zanubrutinib 2trametinib 2talquetamab 2revumenib 2pirtobrutinib 2pegaspargase 2ivosidenib 2idelalisib 2ibrutinib 2fludarabine 2decitabine and cedazuridine drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × immunotoxin HA22 × Other hematologic neoplasm × Clear all
NCT01829711 2020-04-08

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

MedImmune LLC

Phase 3 Completed
80 enrolled 32 charts 1 FDA
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡